Lead: The Centers for Disease Control and Prevention reports that flu activity is rising nationwide this season, with an estimated 4.6 million illnesses, 49,000 hospitalizations and 1,900 deaths so far. New York City and several states are seeing elevated respiratory illness levels, while the majority of sequenced viruses are A(H3N2), driven by a subclade called K. Public health officials note mutations in the circulating viruses create some mismatch with this season’s vaccine, but experts stress vaccination still reduces severe outcomes.
Key takeaways
- The CDC estimates 4.6 million flu illnesses, 49,000 hospitalizations and 1,900 deaths in the U.S. this season to date.
- About 90% of over 900 recent flu specimens were influenza A(H3N2); of those genetically characterized further, nearly 90% belong to subclade K.
- States reporting “moderate” respiratory illness activity include Alabama, Colorado, Connecticut, Hawaii, Louisiana, Maryland, Minnesota, New Hampshire, New Jersey, Ohio, Rhode Island and Texas; New York City shows some of the highest activity.
- Two pediatric flu deaths were reported this week, bringing the season total to three; last season recorded 288 pediatric deaths nationwide.
- Approximately 140 million flu vaccine doses have been distributed this season so far versus 128 million last season.
- Child vaccination coverage is around 40% this season, roughly 10 percentage points below pre-pandemic levels, according to CDC reporting.
Background
Seasonal influenza circulates annually and typically intensifies in late fall and winter as people spend more time indoors. Influenza A(H3N2) subtypes historically cause larger outbreaks among older adults and can be linked to higher hospitalization rates in severe seasons. Public health agencies sequence a sample of circulating viruses to monitor genetic changes that may affect vaccine effectiveness and severity.
States collect and report outpatient respiratory illness levels to the CDC, which publishes weekly national and regional summaries. Reporting became more standardized after 2004, when pediatric influenza death reporting became mandatory for states. Vaccination campaigns aim to reduce both transmission and, crucially, severe outcomes such as hospitalizations and deaths.
Main event
The CDC’s most recent surveillance update shows influenza activity rising across much of the United States, with granular data pointing to pockets of moderate activity and localized higher levels. New York City has reported some of the highest levels of influenza-like illness this season, and a set of 12 states are currently categorized as having moderate respiratory illness activity. All remaining states are in the low or very low categories in the latest weekly summary.
Virologic testing of hundreds of samples sent to CDC labs found that just over 900 specimens were typed, and roughly nine in ten were influenza A(H3N2). Among those that underwent additional genetic analysis, nearly 90% were assigned to subclade K, a variant with several mutations in antigenic sites compared with the vaccine reference strain.
The CDC cautions that those mutations create some degree of antigenic mismatch with this season’s vaccine composition. Nevertheless, agency guidance and outside experts emphasize that the vaccine retains substantial protection against severe disease. Epidemiologist and ABC News medical contributor John Brownstein summarized the position that, despite mismatch, vaccination still lowers the risk of hospitalization and death.
Analysis & implications
The predominance of A(H3N2) subclade K has practical implications for both clinicians and public health planners. H3N2-dominant seasons often stress hospital capacity because the subtype disproportionately affects the elderly and those with chronic conditions who are more likely to require inpatient care. The season-to-date hospitalization figure of 49,000 underlines the potential burden should activity continue to climb through the winter months.
Vaccine mismatch does not equal vaccine failure. Even with antigenic differences, vaccination primes immune responses that can blunt disease severity, shorten illness duration and reduce complications. That protective effect is especially important for vulnerable groups: children under 5, adults 65 and older, pregnant people, and individuals with chronic health conditions.
Declining pediatric vaccination coverage is a concern: roughly 40% of children receiving influenza vaccine this season represents a 10 percentage-point drop from pre-pandemic levels, which may partly explain why most pediatric deaths in the previous season occurred in unvaccinated children. Lower vaccine uptake, coupled with a variant-driven rise in cases, raises the risk of both increased pediatric and adult hospitalizations.
Comparison & data
| Metric | This season (to date) | Last season (reference) |
|---|---|---|
| Estimated illnesses | 4.6 million | — |
| Hospitalizations | 49,000 | — |
| Deaths | 1,900 | — |
| Pediatric deaths | 3 (season-to-date) | 288 (last season, final) |
| Vaccine doses distributed | 140 million | 128 million |
The table highlights available, comparable figures: vaccine distribution has increased from 128 million doses last season to 140 million this season, while the CDC’s current season-to-date illness, hospitalization and death estimates stand at 4.6 million, 49,000 and 1,900 respectively. Pediatric deaths are being tracked weekly; last season’s final pediatric total was 288. Some season-to-date metrics are provisional and will be revised as additional reporting is completed.
Reactions & quotes
Public health officials are urging vaccination and standard prevention measures as activity rises. The CDC reiterates its routine recommendation that everyone aged 6 months and older receive an annual influenza vaccine.
“Even with this new variant and some mismatch with the vaccine, getting a flu shot is still absolutely worth it,”
John Brownstein, epidemiologist and ABC News medical contributor
Brownstein’s remark underscores the distinction between reduced vaccine match and retained protection against severe outcomes. Experts say preventing hospitalizations and deaths remains the primary benefit of vaccination this season.
“This is the time of year when flu typically starts to take off, and we expect activity to continue increasing in the weeks ahead,”
CDC spokesperson (weekly surveillance update)
The CDC’s routine commentary frames the current pattern as typical seasonality amplified by variant circulation and holiday travel, noting that congregate indoor settings can accelerate spread.
Unconfirmed
- Whether subclade K is definitively associated with higher intrinsic severity than other A(H3N2) viruses remains under investigation and is not established in current surveillance data.
- Exact drivers of the recent drop in pediatric vaccination compared with pre-pandemic levels are multifactorial and not fully confirmed in available datasets.
- The degree to which this season’s antigenic differences will alter end-of-season vaccine effectiveness estimates is still being determined by ongoing studies.
Bottom line
The CDC’s update shows a clear uptick in influenza activity with 4.6 million illnesses, 49,000 hospitalizations and 1,900 deaths reported so far this season. The dominance of A(H3N2), and specifically subclade K among sequenced viruses, has produced antigenic changes that create some mismatch with the current vaccine.
Despite that mismatch, public health authorities and outside experts agree vaccination remains the best single tool to reduce severe outcomes, and the CDC continues to recommend annual vaccination for everyone aged 6 months and older. With holiday gatherings and increased travel likely to accelerate transmission, timely vaccination and standard prevention measures (staying home when sick, hand hygiene) are prudent steps to limit further strain on hospitals.
Sources
- ABC News (news report summarizing CDC weekly surveillance)
- Centers for Disease Control and Prevention (official weekly influenza surveillance)